nach oben

Current Colorectal Cancer Reports

Erschienen in:

26.11.2018 | Radiation Therapy and Radiation Therapy Innovations in Colorectal Cancer (JY Wo, Section Editor)

What Is the Future of Circulating Tumor Cells in Colorectal Cancer?

verfasst von: Yun Deng, Hui Zhang, Zhen Zhang

Erschienen in: Current Colorectal Cancer Reports | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To introduce recent progress on circulating tumor cell (CTC) research in colorectal cancer (CRC) and to highlight clinical application of CTCs from detection to assessment of treatment response.

Recent Findings

CTC biological characteristics in CRC play an important role in the detection of CTCs. The in vitro culture of CTCs from CRC patients (cell lines and organoids) can potentially facilitate rapid drug testing and treatment prediction. CTC detection should be standardized with improved detection rate in CRC; further, clinical investigation is still needed to clarify its potential as a tool for early CRC detection, a predictive and prognostic marker to ultimately guide treatment.

Summary

Gaining an improved understanding of CTCs characteristics and ultimately, integration of CTC detection and utilization of CTCs may lead to optimized tumor treatment and facilitate precision medicine.

Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014;4(6):650–61.CrossRefPubMedPubMedCentral

Abdallah EA, Fanelli MF, Buim MEC, Machado Netto MC, Gasparini Junior JL, Souza E, et al. Thymidylate synthase expression in circulating tumor cells: a new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. Int J Cancer. 2015;137(6):1397–405.CrossRefPubMedPubMedCentral

• Mostert B, Jiang Y, Sieuwerts AM, Wang H, Bolt-De Vries J, Biermann K, et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer. 2013;133(1):130–41 The paper revealed consensus and disparity between CTCs and tumors, which should be considered into tumor evaluation and analysis. CrossRefPubMed

Divella R, Daniele A, Abbate I, Bellizzi A, Savino E, Simone G, et al. The presence of clustered circulating tumor cells (CTCs) and circulating cytokines define an aggressive phenotype in metastatic colorectal cancer. Cancer Causes Control. 2014;25(11):1531–41.CrossRefPubMed

Gogenur M, Hillig T, Gogenur I. CytoTrack analysis reveals low presence of circulating tumor cells in the perioperative period in patients with non-metastatic colorectal cancer. Anticancer Res. 2017;37(6):3099–103 Available from: http://ar.iiarjournals.org/content/37/6/3099.abstract.

• Kochall S, Thepkaysone M-L, García SA, Betzler AM, Weitz J, Reissfelder C, et al. Isolation of circulating tumor cells in an orthotopic mouse model of colorectal cancer. J Vis Exp. 2017;(125):1–7. Available from: https://www.jove.com/video/55357/isolation-circulating-tumor-cells-an-orthotopic-mouse-model. Detailed protocol for CTCs inverstigation in animal model.

Scholch S, Garcia SA, Iwata N, Niemietz T, Betzler AM, Nanduri LK, et al. Circulating tumor cells exhibit stem cell characteristics in an orthotopic mouse model of colorectal cancer. Oncotarget. 2016;7(19).

•• Grillet F, Bayet E, Villeronce O, Zappia L, Lagerqvist EL, Lunke S, et al. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture. Gut. 2017;66(10):1802–10 A pioneer study on the in vitro culture of CTCs from CRC patients. CrossRefPubMed

Steinert G, Schölch S, Niemietz T, Iwata N, García SA, Behrens B, et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res. 2014;74(6):1694–704.CrossRefPubMed

10.

• Yokobori T, Iinuma H, Shimamura T, Imoto S, Sugimachi K, Ishii H, et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 2013;73(7):2059–69. A novel molecular for CTC analysis in colorectal cancer. CrossRefPubMed

11.

Sugimachi K, Yokobori T, Iinuma H, Ueda M, Ueo H, Shinden Y, et al. Aberrant expression of plastin-3 via copy number gain induces the epithelial–mesenchymal transition in circulating colorectal cancer cells. Ann Surg Oncol. 2014;21(11):3680–90.CrossRefPubMed

12.

Chen L, Peng M, Li N, Song Q, Yao Y, Xu B, et al. Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer. Sci Rep. 2018;8(1):1188 Available from: http://www.nature.com/articles/s41598-018-19391-1.CrossRefPubMedPubMedCentral

13.

Gorges TM, Penkalla N, Schalk T, Joosse SA, Riethdorf S, Wikman H, et al. Enumeration and molecular characterization of tumor cells in lung cancer patients using a novel in vivo device for capturing circulating tumor cells. 2016;8:2197–207.

14.

Hao N, Zhang JXJ. Microfluidic screening of circulating tumor biomarkers toward liquid biopsy. Sep Purif Rev. 2018;47(1):19–48 Available from: http://www.nature.com/articles/s41598-018-19391-1.CrossRef

15.

Pesta M, Fichtl J, Kulda V, Topolcan O, Treska V. Monitoring of circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. Anticancer Res. 2013;33(5):2239–43.PubMed

16.

Lee A-W, Lin F-X, Wei P-L, Jian-Wei G, Chen J-K. Binary-blend fibber-based capture assay of circulating tumor cells for clinical diagnosis of colorectal cancer. J Nanobiotechnol. 2018;16(1):4 Available from: https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-017-0330-1.CrossRef

17.

Hillig T, Horn P, Nygaard AB, Haugaard AS, Nejlund S, Brandslund I, et al. In vitro detection of circulating tumor cells compared by the CytoTrack and Cell Search methods. Tumor Biol. 2015;36(6):4597–601.CrossRef

18.

Oh BY, Kim J, Lee WY, Kim HC. A New Size-based Platform for Circulating Tumor Cell Detection in Colorectal Cancer Patients. Clin Colorectal Cancer [Internet]. 2017;16(3):214–9. https://doi.org/10.1016/j.clcc.2017.01.007.CrossRefPubMed

19.

Buim ME, Fanelli MF, Souza VS, Romero J, Abdallah EA, Mello C AL, et al. Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer. Cancer Biol Ther [Internet]. 2015;16(9):1289–95. Available from: http://www.tandfonline.com/doi/full/10.1080/15384047.2015.1070991.

20.

Abdallah EA, Fanelli MF, Souza e Silva V, Machado Netto MC, Gasparini Junior JL, Araújo DV, et al. MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in metastatic colorectal cancer. Int J Cancer. 2016;139(4):890–8.CrossRefPubMed

21.

Matikas A, Voutsina A, Lagoudaki E, Hatzidaki D, Trypaki M, Stoupis G, et al. Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer. Transl Oncol [Internet]. 2017;10(4):693–8. https://doi.org/10.1016/j.tranon.2017.06.005.CrossRef

22.

Lemaire CA, Liu SZ, Wilkerson CL, Ramani VC, Barzanian NA, Huang K-W, et al. Fast and Label-Free Isolation of Circulating Tumor Cells from Blood: From a Research Microfluidic Platform to an Automated Fluidic Instrument, VTX-1 Liquid Biopsy System. SLAS Technol Transl Life Sci Innov [Internet]. 2018;23(1):16–29. Available from: http://journals.sagepub.com/doi/10.1177/2472630317738698.

23.

Tan K, Leong SM, Kee Z, Caramat PV, Teo J, MVM B, et al. Longitudinal monitoring reveals dynamic changes in circulating tumor cells (CTCs) and CTC-associated miRNAs in response to chemotherapy in metastatic colorectal cancer patients. Cancer Lett [Internet]. 2018;423:1–8. https://doi.org/10.1016/j.canlet.2018.02.039.CrossRef

24.

Tsai WS, Chen JS, Shao HJ, Wu JC, Lai JM, Lu SH, et al. Circulating Tumor Cell Count Correlates with Colorectal Neoplasm Progression and Is a Prognostic Marker for Distant Metastasis in Non-Metastatic Patients. Sci Rep [Internet]. 2016;6(3):4–11. https://doi.org/10.1038/srep24517.CrossRef

25.

Harb W, Fan A, Tran T, Danila DC, Keys D, Schwartz M, et al. Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay. Transl Oncol [Internet]. 2013;6(5):528-IN1. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1936523313800496.

26.

Hinz S, Hendricks A, Wittig A, Schafmayer C, Tepel J, Kalthoff H, et al. Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study. BMC Cancer [Internet]. 2017;17(1):1–11. https://doi.org/10.1186/s12885-016-3035-1.CrossRef

27.

Barbazan J, Muinelo-Romay L, Vieito M, Candamio S, Diaz-Lopez A, Cano A, et al. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer. Int J Cancer. 2014;135(11):2633–43.CrossRefPubMed

28.

Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, et al. Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Mol Cancer Ther [Internet]. 2015;14(10):2401–8. Available from: http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-15-0359.

29.

Bielčiková Z, Jakabová A, Pinkas M, Zemanová M, Kološtová K, Bobek V. Circulating tumor cells: What we know, what do we want to know about them and are they ready to be used in clinics? Am J Transl Res. 2017;9(6):2807–23.PubMedCentralPubMed

30.

Eliasova P, Pinkas M, Kolostova K, Gurlich R, Bobek V. Circulating tumor cells in different stages of colorectal cancer. Folia Histochem Cytobiol. 2017;55(1):1–5.CrossRefPubMed

31.

•• Sotelo MJ, Sastre J, Maestro ML, Veganzones S, Viéitez JM, Alonso V, et al. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. Ann Oncol. 2015;26(3):535–41. A large prospective multicenter study on the potential prognostic value of CTC in stage III CRC patients showed CTC detection was not associated with worse DFS and OS in patients with stage III CRC, which means cautions are needed when considering the CTC clinical relevance including the CTC detection methods. CrossRefPubMed

32.

Santos MF, VKR M, Craft BS, Puneky LV, Sheehan NT, Lewis RE, et al. Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells. Exp Mol Pathol [Internet]. 2014;96(3):367–74. https://doi.org/10.1016/j.yexmp.2014.04.001.CrossRef

33.

•• Musella V, Pietrantonio F, Di Buduo E, Iacovelli R, Martinetti A, Sottotetti E, et al. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. Int J Cancer. 2015;137(6):1467–74. A prospective, observational study on the role CTCs in CRC patients received target therapy, and revealed its application in colorectal cancer treatment. CrossRefPubMed

34.

Vojtechova G, Benesova L, Belsanova B, Minarikova P, Levy M, Lipska L, et al. Monitoring of Circulating Tumor Cells by a Combination of Immunomagnetic Enrichment and RT-PCR in Colorectal Cancer Patients Undergoing Surgery. Adv Clin Exp Med [Internet]. 2016;25(6):1273–9. Available from: http://www.advances.umed.wroc.pl/en/article/2016/25/6/1273/.

35.

Kidess-Sigal E, Liu HE, Triboulet MM, Che J, Ramani VC, Visser BC, et al. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. Oncotarget [Internet]. 2016;7(51):85349–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27863403.

36.

Rawal S, Yang Y-P, Cote R, Agarwal A. Identification and Quantitation of Circulating Tumor Cells. Annu Rev Anal Chem [Internet]. 2017;10(1):321–43. Available from: http://www.annualreviews.org/doi/10.1146/annurev-anchem-061516-045405.

37.

Xu L, Mao X, Imrali A, Syed F, Mutsvangwa K. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System. 2015;1–23.

38.

• Germano G, Mauri G, Siravegna G, Dive C, Pierce J, Di Nicolantonio F, et al. Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. Clin Colorectal Cancer [Internet]. 2017;1–4. https://doi.org/10.1016/j.clcc.2017.10.017. Good perspectives for CTCs and ctDNA application.

39.

Yang C, Zhuang W, Hu Y, Zhu L. Clinical significance of peripheral circulating tumor cell counts in colorectal polyps and non-metastatic colorectal cancer. World J Surg Oncol [Internet]. 2018;16(1):13. Available from: https://wjso.biomedcentral.com/articles/10.1186/s12957-017-1305-2.

40.

Denève E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daurès JP, et al. Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem. 2013;59(9):1384–92.CrossRefPubMed

41.

Welinder C, Jansson B, Lindell G, Wenner J. Cytokeratin 20 improves the detection of circulating tumor cells in patients with colorectal cancer. Cancer Lett [Internet]. 2015;358(1):43–6. https://doi.org/10.1016/j.canlet.2014.12.024.CrossRefPubMed

42.

Tseng JY, Yang CY, Liang SC, Liu RS, Yang SH, Lin JK, et al. Interleukin-17A modulates circulating tumor cells in tumor draining vein of colorectal cancers and affects metastases. Clin Cancer Res. 2014;20(11):2885–97.CrossRefPubMed

43.

Matsusaka S, Kozuka M, Takagi H, Ito H, Minowa S, Hirai M, et al. A novel detection strategy for living circulating tumor cells using 5-aminolevulinic acid. Cancer Lett [Internet]. 2014;355(1):113–20. https://doi.org/10.1016/j.canlet.2014.09.009.CrossRefPubMed

44.

Seeberg LT, Brunborg C, Waage A, Hugenschmidt H, Renolen A, Stav I, et al. Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases. Ann Surg Oncol. 2017;24(8):2113–21.CrossRefPubMedPubMedCentral

45.

•• Aggarwal C, Meropol NJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol. 2013;24(2):420–8. Wholly analysis about CTCs and other clinical parameters in colorectal cancer patients to domonstrate CTCs role in tumor metastasis. CrossRefPubMed

46.

Dalum GV, Stam G-J, Scholten LFA, Mastboom WJB, Vermes I, Tibbe AGJ, Groot MRDE, Terstappen LWMM. Importance of circulating tumor cells in newly diagnosed colorectal cancer. Int J Oncol [Internet]. 2015;46(3):1361–8. Available from: https://www.spandidos-publications.com/.

47.

Andree KC, van Dalum G, Terstappen LWMM. Challenges in circulating tumor cell detection by the CellSearch system. Mol Oncol [Internet]. 2016;10(3):395–407. https://doi.org/10.1016/j.molonc.2015.12.002.CrossRef

48.

Kaifi JT, Kunkel M, Dicker DT, Joude J, Allen JE, Das A, et al. Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver. Cancer Biol Ther. 2015;16(5):690–8.CrossRefPubMedPubMedCentral

49.

Romiti A, Raffa S, Di Rocco R, Roberto M, Milano A, Zullo A, et al. Circulating tumor cells count predicts survival in colorectal cancer patients. J Gastrointestin Liver Dis [Internet]. 2014;23(3):279–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25267956.

50.

Lalmahomed ZS, Mostert B, Onstenk W, Kraan J, Ayez N, Gratama JW, et al. Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases. Br J Cancer. 2015;112(3):556–61.CrossRefPubMedPubMedCentral

51.

Vaiopoulos AG, Kostakis ID, Gkioka E, Christopoulos P, Gogas H, Kouraklis G, et al. Detection of Circulating Tumor Cells in Colorectal and Gastric Cancer Using a Multiplex PCR Assay. Anticancer Res. 2014;34(6):3083–92.PubMed

52.

Barbazan J, Dunkel Y, Li H, Nitsche U, Janssen KP, Messer K, et al. Prognostic Impact of Modulators of G proteins in Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer. Sci Rep [Internet]. 2016;6(February):1–12. https://doi.org/10.1038/srep22112.CrossRef

53.

Katoh S, Goi T, Naruse T, Ueda Y, Kurebayashi H, Nakazawa T, et al. Cancer stem cell marker in circulating tumor cells: Expression of CD44 variant exon 9 is strongly correlated to treatment refractoriness, recurrence and prognosis of human colorectal cancer. Anticancer Research. 2015;35(1):239–44.PubMed

54.

Nesteruk D, Rutkowski A, Fabisiewicz S, Pawlak J, Siedlecki JA, Fabisiewicz A. Evaluation of prognostic significance of circulating tumor cells detection in rectal cancer patients treated with preoperative radiotherapy: prospectively collected material data. Biomed Res Int. 2014;2014:712827.CrossRefPubMedPubMedCentral

55.

Hinz S, Röder C, Tepel J, Hendricks A, Schafmayer C, Becker T, et al. Cytokeratin 20 positive circulating tumor cells are a marker for response after neoadjuvant chemoradiation but not for prognosis in patients with rectal cancer. BMC Cancer [Internet]. 2015;15(1):1–7. https://doi.org/10.1186/s12885-015-1989-z.CrossRef

56.

• Krebs MG, Renehan AG, Backen A, Gollins S, Chau I, Hasan J, et al. Circulating tumor cell enumeration in a phase II trial of a four-drug regimen in advanced colorectal cancer. Clin Colorectal Cancer [Internet]. 2015;14(2):115–22. https://doi.org/10.1016/j.clcc.2014.12.006. This study utilized a phase II trial of a 4-drug regimen to dertermine CTCs' role in treatment guidement. CrossRefPubMed

57.

Martin OA, Anderson RL, Narayan K, MacManus MP. Does the mobilization of circulating tumour cells during cancer therapy cause metastasis? Nat Rev Clin Oncol [Internet]. 2017;14(1):32–44. https://doi.org/10.1038/nrclinonc.2016.128.CrossRefPubMed

58.

• Ilie M, Hofman V, Leroy S, Cohen C, Heeke S, Cattet F, et al. Use of circulating tumor cells in prospective clinical trials for NSCLC patients – standardization of the pre-analytical conditions. 2018;1–10. A guide referrence in CTCs detection standardization.

59.

Wong KHK, Tessier SN, Miyamoto DT, Miller KL, Bookstaver LD, Carey TR, et al. Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells. Nat Commun [Internet]. 2017;8(1):1733. Available from: http://www.nature.com/articles/s41467-017-01705-y.

60.

Huang X, Yang Y, Zhao Y, Cao D, Ai X, Zeng A, et al. RhoA-stimulated intra-capillary morphology switch facilitates the arrest of individual circulating tumor cells. Int J Cancer [Internet]. 2018; Available from: http://doi.wiley.com/10.1002/ijc.31238.

61.

Del Vecchio F, Mastroiaco V, Di Marco A, Compagnoni C, Capece D, Zazzeroni F, et al. Next-generation sequencing: Recent applications to the analysis of colorectal cancer. J Transl Med [Internet]. 2017;15(1):1–19. https://doi.org/10.1186/s12967-017-1353-y.CrossRef

62.

• Liu HE, Triboulet M, Zia A, Vuppalapaty M, Kidess-Sigal E, Coller J, et al. Workflow optimization of whole genome amplification and targeted panel sequencing for CTC mutation detection. npj Genomic Med [Internet]. 2017;2(1):34. Available from: http://www.nature.com/articles/s41525-017-0034-3. A good guidance for the CTC detection standardization.

63.

• Praharaj PP, Bhutia SK, Nagrath S, Bitting RL, Deep G. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. Biochim Biophys Acta - Rev Cancer [Internet]. 2018; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0304419X1730210X. An important outlook for CTCs study in colorectal cancer.

64.

Mohamed Suhaimi NA, Foong YM, Lee DY, Phyo WM, Cima I, Lee EX, et al. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. Mol Oncol [Internet]. 2015;9(4):850–60. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1574789114002968%5Cnhttp://ac.els-cdn.com/S1574789114002968/1-s2.0-S1574789114002968-main.pdf?_tid=eebfd432-0aef-11e5-927e-00000aab0f6b&acdnat=1433446312_2452e531114dddfa0cab4701fc93dc59.

65.

Lyberopoulou A, Aravantinos G, Efstathopoulos EP, Nikiteas N, Bouziotis P, Isaakidou A, et al. Mutational analysis of circulating tumor cells from colorectal cancer patients and correlation with primary tumor tissue. PLoS One. 2015;10(4):1–12.CrossRef

66.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol [Internet]. 2018;JCO.2017.76.867. Available from: http://ascopubs.org/doi/10.1200/JCO.2017.76.8671.

67.

Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63(2):317–25.CrossRefPubMed

68.

Khoo BL, Grenci G, Lim YB, Lee SC, Han J, Lim CT. Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device. Nat Protoc [Internet]. 2018;13(1):34–58. https://doi.org/10.1038/nprot.2017.125.CrossRefPubMed

Titel: What Is the Future of Circulating Tumor Cells in Colorectal Cancer?
verfasst von: Yun Deng
Hui Zhang
Zhen Zhang
Publikationsdatum: 26.11.2018
Verlag: Springer US
Erschienen in: Current Colorectal Cancer Reports / Ausgabe 6/2018
Print ISSN: 1556-3790
Elektronische ISSN: 1556-3804
DOI: https://doi.org/10.1007/s11888-018-0418-5

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

What Is the Future of Circulating Tumor Cells in Colorectal Cancer?